Resverlogix Presents Two Abstracts on Analysis of the Phase 2 ASSERT Clinical Trial at The ESC Congress 2011

Calgary (ots/PRNewswire) -

Resverlogix Corp. ("Resverlogix") announced today that two
abstracts on the analysis of the ASSERT trial were presented at the
European Society of Cardiology (ESC) Congress 2011 in Paris, France.
The abstracts were co-authored by Resverlogix Senior Scientists and
Clinical Steering Committee members: S.J. Nicholls, A. Gordon, J.
Johansson, C.M. Ballantyne, J.J.P. Kastelein, N.C.W. Wong, M.
Borgman, K. Wolski, and S.E. Nissen.

The Phase 2 ASSERT clinical trial's lead compound RVX-208 is an
orally active small molecule that raises Apolipoprotein A-I (ApoA-I)
production, the key protein in high-density lipoprotein (HDL) known
as the 'good cholesterol'. Data gathered in the ASSERT trial showed
that RVX-208 enhanced biomarkers of reverse cholesterol transport
(RCT), thus reflecting robust cholesterol clearance from arterial
wall plaques via this metabolic pathway. This action of RVX-208 is
unique and when added to new knowledge of the target protein bound by
the compound, it indicates that RVX-208 is clearly different from all
other drugs in the sphere, including cholesteryl ester transfer
protein (CETP) inhibitors.

The current analysis of the ASSERT trial yielded new findings
summarized in the presentation titled: "Increasing Circulating
Concentration of all HDL Particle Subclasses in Hyper-Responders:
Insights from the ASSERT Study to ApoA-I Induction." Abstract link:
http://spo.escardio.org/AbstractDetails.aspx?id=100468&eevtid=48

Dr. Jan Johansson, Resverlogix's Senior Vice President of Medical
Affairs, highlighted the significance of this observation noting
that, "enhanced RCT is a highly sought after goal in drug development
because it gives us a chance to regress atherosclerosis within the
vessel wall. This new data helped identify a large high-risk patient
population with low HDL levels whereby significant benefit may be
gained from the actions of RVX-208."

The second ESC presentation titled: "Apolipoprotein A-I Induction
Therapy is Associated with Reduction in Inflammatory Biomarkers:
Potential Implications for Functionality of High-Density
Lipoproteins," demonstrated the potential of RVX-208 in lowering CRP,
a recognized biomarker of cardiovascular risk and inflammation.
Abstract link:
http://spo.escardio.org/AbstractDetails.aspx?id=97764&eevtid=48

"These new observations are valuable in advancing our Phase 2b
ASSURE clinical trial of RVX-208 to examine atherosclerosis
regression using intravascular ultrasound (IVUS) and biomarkers of
RCT for 26 weeks in patients with Coronary Artery Disease," said
Donald J. McCaffrey, President & Chief Executive Officer of
Resverlogix. "This new data in the two ESC presentations has not only
enriched our understanding of how RVX-208 can augment RCT, and thus
enable regression of atherosclerosis, but also the expanded
therapeutic potential of RVX-208 in alternate indications."

About RVX-208

RVX-208 is a novel small molecule therapeutic that facilitates
endogenous ApoA-I production. It is positioned to be one of the most
promising emerging drugs in development for the treatment of
atherosclerosis. To the Company's knowledge, RVX-208 is the only
novel small molecule that is specifically designed to increase ApoA-I
production and thereby raise HDL levels thus enhancing HDL
functionality to augment RCT and ultimately plaque regression. RCT is
a pathway by which cholesterol that has accumulated within the
arterial wall can be transported to the liver for excretion, thus
reducing or preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet medical needs. The NexVas(TM) Plaque
Regression program is the Company's primary focus which is to develop
novel small molecules that enhance ApoA-I production. These vital
therapies are focused to address the burden of atherosclerosis and
other important diseases such as Acute Coronary Syndrome, Alzheimer's
disease, Peripheral Artery Disease, and Autoimmune diseases.
Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange
. For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking information
as defined under applicable Canadian securities legislation,
including our statements with respect to research, development and
commercialization of novel therapeutics that reduce the risk of
cardiovascular and autoimmune diseases including atherosclerosis,
diabetes, Alzheimer's disease, Peripheral Artery Disease and other
vascular disorders that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous known and unknown
risks and uncertainties including but not limited to those risk
factors discussed in the Company's Annual Information Form and
January 31, 2011 MD&A which are incorporated herein by reference and
other documents we file from time to time with securities
authorities, which are available through SEDAR at
http://www.sedar.com. The forward-looking statements contained in
this news release are expressly qualified by this cautionary
statement and are made as of the date hereof. The Company disclaims
any intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
The TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

%SEDAR: 00019253E

For further information:
Company Contact:
Donald J. McCaffrey
President & CEO
Resverlogix Corp.
Phone: +1-403-254-9252
Email: Don@resverlogix.com
Sarah K. Zapotichny
Director, Investor Relations
Resverlogix Corp.
Phone: +1-403-254-9252
Email: sarah@resverlogix.com
US Institutional Investors:
Susan Noonan
Managing Partner
S.A. Noonan Communications, LLC
Phone: +1-212-966-3650
Email: Susan@sanoonan.com
Media:
Eric Goldman
Vice President Public Relations
Rx Communications Group
Phone: +1-917-322-2563
Email: egoldman@rxir.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.